• Facebook
  • Twitter
  • LinkedIn
  • Google +
  • RSS

VAXIMM AG - Articles and news items

VAXIMM AG begins journey to single arm study of VXM01 therapy

VAXIMM AG begins journey to single arm study of VXM01 therapy

Industry news / 4 May 2016 / Mandy Parrett, Editorial Assistant

The Swiss-German biotech company, VAXIMM AG, has announced the enrolment of its first patient in a Phase 2a clinical trial for immunotherapy, VXM01.

 

Webinar: Understanding ISO Standards: ISO 14644-2:2015 Cleanroom MonitoringWATCH NOW
+ +